

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.

Wilhem Leconet, Christel Larbouret, Thierry Chardès, Gaëlle Thomas, Madeline Neiveyans, Muriel Busson, Marta Jarlier, Nina Radosevic-Robin, Martine Pugnière, Florence Bernex, et al.

► **To cite this version:**

Wilhem Leconet, Christel Larbouret, Thierry Chardès, Gaëlle Thomas, Madeline Neiveyans, et al.. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.: Anti-AXL mAb for pancreatic cancer immunotherapy. *Oncogene*, Nature Publishing Group, 2014, 33 (47), pp.5405-14. <10.1038/onc.2013.487>. <inserm-00916587>

HAL Id: inserm-00916587

<http://www.hal.inserm.fr/inserm-00916587>

Submitted on 16 May 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SupplementaryInformation

Materials and Methods

Generation of monoclonal antibodies

Balb/c mice were subcutaneously immunized with 10 μ grhAXL-EDC at day 0 in complete Freund adjuvant, 14 and 28 in incomplete Freund adjuvant. Three days after a last intravenous boost, spleen cells were fused with non-secreting P3X63Ag8.653 murinemyeloma cells using polyethylene glycol, as previously described⁽²¹⁾. Antibodies in hybridoma supernatants were screened by ELISA. Hybridoma cells that secreted anti-AXL antibodies were cloned by limiting dilution and cryopreserved. Antibodies were purified on protein G-agarose (Sigma-Aldrich, St Louis, MO) columns, as recommended by the manufacturer, sterilized through 0.2 μ m filters, quantified and stored at -20°C in phosphate buffered saline (PBS).

Fluorescence-Activated Cell sorting (FACS)

Cells were trypsin-detached and incubated with 20 μ g/ml of purified anti-AXL mAbs in PBS/0.1%BSA on ice for 1.5h. After washing, cells were incubated with FITC-conjugated anti-mouse IgGs (Fc specific) (Sigma-Aldrich) on ice in the dark for 1h. Antibody binding to the cells was then quantified (minimum of 10000 events) using a Beckman-Coulter FC500 MPL Flow Cytometer.

ELISA

Maxisorb 96-well plates (Nunc, Paisley, UK) were coated with 200 ng/ml rhAXL, rhMER, rhTYRO3 or rmAxl in PBS at 4°C overnight and then saturated with PBS/0.1% BSA. Purified anti-AXL mAbs were added at 37°C for 2h. After washes, horseradish peroxidase-conjugated anti-mouse antibodies (Sigma-Aldrich) were

added for 1h and *o*-Phenylenediaminedihydrochloride(Sigma-Aldrich) was used as substrate as recommended by the manufacturer. Absorbance was measured at 450 nm with an ELISA plate reader.

Phosphorylated AXL measurement by ELISA

1×10^6 cells were grown in 6-well plates for 24h and then switched to serum-free medium. Cells were then incubated, or not, with 100 $\mu\text{g/ml}$ purified anti-AXL mAbs for 1.5h, followed by 200 ng/ml rhGAS6 for 30 minutes. Cells were then lysed and protein concentration determined with the BC assay Protein Quantitation Kit (Interchim, Montluçon, France). The PathScan® Phospho-Axl (PanTyr) Sandwich ELISA Kit (Cell Signaling Technology) was used for quantifying phosphorylated AXL according to the manufacturer's instructions. Absorbance was measured at 450 nm with an ELISA reader.

Surface Plasmon Resonance analysis by BIACORE

Analysis of the interaction of the anti-AXL mAbs with AXL ECD and of their competition with GAS6 was performed on a BIACORE 3000 instrument (BIACORE AB, Uppsala, Sweden) at 25°C with HBS-EP (10 mM HEPES, 150 mMNaCl, pH 7.4, 0.005% surfactant P20 buffer) as running buffer. Recombinant human AXL-Fc fusion protein was immobilized on a CM5 sensor chip using an amine coupling kit (Biacore AB). The control flow cell was treated only with chemical reagents without protein. For competition studies, a saturating concentration (625 nM) of rhGAS6 was injected onto the AXL-Fc-coated chip before injection of 666 nM anti-AXL mAbs. To validate our results, the reverse experiment (first injection of anti-AXL mAbs and then of rhGAS6) was carried out.